Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook
Pharm Exec: China Invests in Building Biotech (Young & Partners comments – January 2022)
Young & Partners comments on what to expect from China in this article
Chemicals M&A to be resilient in 2022 (ICIS Chemical Business February 11 – February 17 2022)
Young & Partners reviews the developments through yearend and the outlook for 2022
New Supply Chains (ICIS Chemical Business November 26 – December 2 2021)
Takeaways from Senior Chemical Executive Conference Panel on Reimagining Supply Chain Strategies
Chemical Economic, M&A and Financing (ICIS Chemical Business November 19-26 2021)
Comprehensive look at the economic, stock market, M&A and financing trends and outlook
Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)
While activity and outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable
Mixed outlook for chemical financing (ICIS Chemical Business August 27, 2021)
Young & Partners documents slower, but still healthy debt and equity issuance
Chemical M&A market in transition (ICIS Chemical Business August 20, 2021)
Slow M&A market begins to pick up, but with many underlying changes
Pharm Exec: Pharma and Biotech’s 2020 Full-Year View (Young & Partners article – March 2021)
Examines the key biopharma stock numbers and industry trends from a year that challenged like never before
Chemical Industry Financings in 2020 and Outlook (ICIS Chemical Business February 26, 2021)
Chemical debt and equity financing surged due to the pandemic, but outlook still healthy